Cost-Effective Treatment for Crohn's Disease Patients Who Lose Responsiveness to Infliximab

A study in the June issue of CGH looks at whether a test-based or empiric dose-escalation strategy is more cost-effective for treating Crohn's disease patients who have stopped responding to Infliximab. Dr. Kuemmerle speaks to Dr. Fernando S. Velayos.

Source: Clinical Gastroenterology and Hepatology - June 4, 2013 Category: Gastroenterology Authors: AGA Source Type: podcasts